A Study of Ixekizumab in Chinese Participants With Psoriasis Vulgaris

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
The purpose of the study is to research how much ixekizumab enters the bloodstream and how long the body takes to get rid of the drug and the safety of ixekizumab and any side effects that might be associated with it. The study has two parts: A single-dose part and multiple-dose part. The single dose part of this study will last up to 24 weeks, including the screening period. The multiple dose part of this study will last up to 32 weeks including the screening period.
Epistemonikos ID: bec39bd5ace1f7799678af0ed0a0332057ca0d26
First added on: May 20, 2024